Insider Trading Activity Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Director Sold 351 shares of Stock

Insider Trading Activity For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Story continues below

Patrick G Enright , Director of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) reportedly Sold 351 shares of the company’s stock at an average price of 148.4 for a total transaction amount of $52,088.40 SEC Form

Insider Trading History For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

  • On 3/3/2014 Patrick Enright, Director, sold 559,628 with an average share price of $152.39 per share and the total transaction amounting to $85,281,710.92.View SEC Filing
  • On 3/4/2014 Seamus Mulligan, Director, sold 550,000 with an average share price of $156.25 per share and the total transaction amounting to $85,937,500.00.View SEC Filing
  • On 3/6/2014 Fintan Keegan, EVP, sold 4,640 with an average share price of $159.90 per share and the total transaction amounting to $741,936.00.View SEC Filing
  • On 3/10/2014 Jeffrey Tobias, CMO, sold 3,000 with an average share price of $152.99 per share and the total transaction amounting to $458,970.00.View SEC Filing
  • On 4/8/2014 Bruce Cozadd, CEO, sold 5,000 with an average share price of $123.18 per share and the total transaction amounting to $615,900.00.View SEC Filing
  • On 4/14/2014 Jeffrey Tobias, CMO, sold 3,000 with an average share price of $128.54 per share and the total transaction amounting to $385,620.00.View SEC Filing
  • On 4/17/2014 Rick Winningham, Director, sold 27,500 with an average share price of $140.00 per share and the total transaction amounting to $3,850,000.00.View SEC Filing
  • Analyst Ratings For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
    These are 3 Hold Ratings, 16 Buy Ratings .
    The current consensus rating for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is Buy (Score: 2.84) with a consensus target price of $182.84 , a potential (25.16% upside)

    Analyst Ratings History For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

    • On 4/1/2016 Northland Securities Reiterated Rating Outperform with a price target of $175.00
    • On 4/5/2016 Canaccord Genuity Reiterated Rating Buy with a price target of $170.00
    • On 1/18/2017 Barclays PLC Reiterated Rating Overweight with a price target of $200.00
    • On 1/18/2017 Goldman Sachs Group, Inc. (The) Reiterated Rating Buy with a price target of $170.00
    • On 1/19/2017 SunTrust Banks, Inc. Reiterated Rating Buy with a price target of $210.00
    • On 2/16/2017 Guggenheim Reiterated Rating Buy
    • On 2/22/2017 Evercore ISI Initiated Coverage of rating Buy with a price target of $160.00

    Recent Trading Activity for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
    Shares of Jazz Pharmaceuticals PLC closed the previous trading session at 146.09 up +0.09 0.06% with 297,724 shares trading hands.

    An ad to help with our costs